From Surf Wiki (app.surf) — the open knowledge base
Benidipine
Antihypertensive drug of the calcium channel blocker class
Antihypertensive drug of the calcium channel blocker class
| Drugs.com =
| elimination_half-life =
Benidipine is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension). It is a triple L-, T-, and N-type calcium channel blocker. It is reno- and cardioprotective.
It was patented in 1981 and approved for medical use in 1991.
Dosing
Benidipine is dosed as 2–8 mg once daily.
Mechanism
Benidipine is a calcium channel blocker.
Benidipine has additionally been found to act as an antagonist of the mineralocorticoid receptor, or as an antimineralocorticoid.
Names
Other names include Benidipinum or benidipine hydrochloride.
Benidipine is sold as Coniel by Kyowa Hakko Kogyo.
Benidipine is initially licensed for use in Japan and selected Southeast Asian countries and later in Turkey, where it is sold as 4 mg tablets.
References
References
- (2006). "Analogue-based Drug Discovery". John Wiley & Sons.
- Hi-Eisai Pharmaceutical, Inc.. "Coniel (benidipine) package insert (Philippines)". CMPMedica.
- (September 2014). "Is there a new dawn for selective mineralocorticoid receptor antagonism?". Current Opinion in Nephrology and Hypertension.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Benidipine — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report